The drug is currently undergoing a phase III study in patients with acute respiratory distress syndrome after delivering some remarkable results earlier in its development.
Showing 25 of 5337
Astrazeneca has offloaded the US and Canada commercial rights of Zoladex to focus on new oncology medicines.
The former director of education at Apple will also take up the role of vice president of the WideAcademy, WideCells’ research and development and training division.
The company has developed bluetooth-enabled reading devices that allow users to track the results of breath tests using a phone or tablet.
Animalcare has reported 26% growth in underlying profit on the back of higher revenue.
The cell-based therapeutics group featured in the ‘Andrew Marr: My Brain and Me’ documentary last night
Vortex Biosciences' Elodie Sollier-Christen received the 2017 Society award for Laboratory Automation and Screening Innovation.
“This patent grant extends our intellectual property protection in the world's largest pharmaceutical market”
HMPL-453 targets fibroblast growth factor receptors, which are central to several biological processes
The customer is already Horizon's largest generating £1.5mln in revenue in 2016
Dr Nick Plowman will join the AVO board as a non-executive director with immediate effect
Cathal Friel oversaw the switch from an oil and gas explorer to a pharmaceuticals play
Jean-Yves Pavee retired from the board last night and has been replaced by Jeff Barton, who has been nominated by Abbott Laboratories.
Nick Plowman holds 2.6mln shares in AVO, representing 3.6% of the company
Nanobiotix is at the tipping point of its value creation with the coming first Phase II/III interim readout and a potential first market approval this year, the new COO said
Episalvan offers a potential breakthrough for sufferers of Epidermolysis Bullosa (EB), a rare and hard to treat genetic disorder that causes exceptionally fragile skin.
As reported last month, Sinophi had cancelled two purchase orders it made back in 2015.
The FSS group is the largest integrated healthcare system in the US covering almost 9mln people
The firm said it expects 2017 to be dominated by sales of the heparin test as its focus on big networks, such as the Greater New York Hospital Association, continues to bear fruit.
The company is developing Polyvac as a short course of injections that is safer and more effective than the current treatments.
First European market authorisation, a CE Mark, is expected in 2017
The update was provided as Scancell served up its financial results for the six months ended October 31.
Chief executive David Budd said: "We are making good progress towards realising the proven potential of the Genedrive platform in a range of applications through our own programmes and partnerships.”
Current non-executive director Tim Lebus is to step down, making way for Steve Myers and Hans von Celsing to join the board
The company's update reveals a company in rude health